CSGALNACT2 and bladder transitional cell carcinoma: Additionally, CSGALNACT2 was also decreased in a variety of cancer types, such as bladder Urothelial Carcinoma (BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), kidney Chromophobe (KICH), Uterine Corpus Endometrial Carcinoma (UCEC) (Fig. 1C and Supplementary Fig. 1A).